Aeon Biopharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
AEON Biopharma, Inc. reports significant losses and going concern doubt in its 2025 annual filing, while advancing its ABP-450 botulinum toxin biosimilar program with positive analytical study results and strategic financing efforts.
AMEX
AEON Biopharma, Inc. has filed an amendment to its 2024 Annual Report on Form 10-K to include inadvertently omitted corporate governance documents, specifically related to its Certificate of Incorporation and Bylaws, without altering any financial or other previously reported information.
AMEX
AEON Biopharma's latest 10-K filing highlights a strategic pivot towards a biosimilar regulatory pathway for ABP-450, while also acknowledging substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional financing.
AMEX
AEON Biopharma has filed an amendment to its annual report to include exhibits that were inadvertently omitted in the original filing.
AMEX
10-K/A: AEON Biopharma Restates 2023 Financials Due to Accounting Error, Cites Going Concern Uncertainty
AEON Biopharma files an amended annual report restating its 2023 financials due to an accounting error related to acquired research and development, and expresses substantial doubt about its ability to continue as a going concern.
AMEX
AEON Biopharma's annual 10-K filing highlights concerns about its ability to continue as a going concern, despite ongoing clinical trials for its lead product candidate, ABP-450.